Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Gyre Therapeutics, Inc.

35 indications, side-by-side phase, drug & LoA

$5.93

-0.13 (-2.15%)

C 51Pipeline Score Fair Value Pharma · Commercial
Market Cap
587.78 M
EPS
-0.07
P/E Ratio
-
Value Trade
405.56 K
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    22.52 M

  • R&D Expenses

    6.74 M

  • Operating CF

    3.18 M

  • Total Assets

    162.01 M

  • Total Liabilities

    25.03 M

  • Equity

    101.31 M

  • D/E Ratio

    12,345

-11.79 %
Week
-23.48 %
1 Month
-27.77 %
3 Month
-18.33 %
6 Month
-90.75 %
5 Year
-99.96 %
All Time
Cash Data
Profitable

  • Cash Position

    49.81 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 8, 2026
Overview
Volume
81.59 K
52 Week Range
5.97 - 11.61
% held by Insiders
81.79 %
% held by Institutions
3.53 %
Enterprise Value
574.47 M
Total Shares
96.94 M
Short %
9.38 %
Float Shares
17.84 M
Company Description
HQ: 12730 HIGH BLUFF DRIVE, SAN DI...
Employees:618
https://www.gyretx.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
phase 3 data readout example
Phase 3
—
Small Molecules
Respiratory System
Phase 3
—
Small Molecules
Respiratory System
Phase 3
—
Small Molecules
Respiratory System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C51
Pipeline Score
$989M
Pipeline Value
Fair Value
Valuation Signal
4
Drugs Scored
1.7x
rNPV / MCap
Top 79%
Micro Cap
(rank 191 of 905)
Percentile Rank
Gyre Therapeutics, Inc. carries a moderate pipeline score (51/100), with $4.9B risk-adjusted pipeline value, led by Coagulation Factor IX variant in Hemophilia B (Phase 2), across $53B in total addressable markets.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
Coagulation Factor IX variant
Monoclonal antibody		Hemophilia BPhase 2NCT0399578445% $1.9B COMPLETED 6 - -Apr 1, 2020 -Aug 8, 2021
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
Hydronidone
CHB-associated liver fibrosis
Phase 3
2025-08-12
Hydronidone
CHB-associated liver fibrosis
Phase 3
2025-08-12
Hydronidone
CHB-associated liver fibrosis
Phase 3
2025-08-12
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in GYRE
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
GYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
GYRE
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
GYRE Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
GYRE Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2027-01-15 0.00 0 - - - - - -
2027-01-15 0.00 0 - - - - - -
2027-01-15 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Gyre Therapeutics, Inc. (GYRE) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How GYRE ranks across every disease it competes in
No competitive intelligence available for GYRE.